Higher FVIII Blood Levels Seen and Better Maintained with Jivi Than Eloctate, Phase 1 Study in Severe Hemophilia A Finds
Bayer’s Jivi, an FVIII replacement therapy for hemophilia A, has a longer half-life and a slower clearance from blood circulation than Eloctate, and may protect against bleeding for longer periods, results of a Phase 1 trial in people with severe disease suggests. The study “Direct comparison of…